A Cancer Conundrum: Too Many Drug Trials, Too Few Patients


“With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented in medical research.

“There are too many experimental cancer drugs in too many clinical trials, and not enough patients to test them on.

“The logjam is caused partly by companies hoping to rush profitable new cancer drugs to market, and partly by the nature of these therapies, which can be spectacularly effective but only in select patients.”

Go to full article published by The New York Times on Aug 12, 2017.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.